CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination With PD-1 Antagonist Nivolumab in Patients With Transformed Chronic Lymphocytic Leukemia (Richter's Transformation) or Non-Hodgkin Lymphoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03884998
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:44.200620+00:00
- Published At
- 2025-12-30T00:00:00+00:00
- Record Updated At
- 2025-12-30
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Chronic Lymphocytic Leukemia", "Diffuse Large B-Cell Lymphoma", "Follicular Lymphoma", "Indolent Non-Hodgkin Lymphoma", "Lymphoplasmacytic Lymphoma", "Marginal Zone Lymphoma", "Richter Syndrome"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-12-30"- protocolSection.identificationModule.nctId
"NCT03884998"- protocolSection.identificationModule.officialTitle
"A Phase I Study of PI3K\u03b1,\u03b4 Inhibitor Copanlisib in Combination With PD-1 Antagonist Nivolumab in Patients With Transformed Chronic Lymphocytic Leukemia (Richter\u0027s Transformation) or Non-Hodgkin Lymphoma"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.